Arbutus Biopharma Corporation (ABUS)
$
3.36
-0.08 (-2.38%)
Key metrics
Financial statements
Free cash flow per share
-0.3083
Market cap
653.1 Million
Price to sales ratio
102.0002
Debt to equity
0.0150
Current ratio
6.0114
Income quality
0.7667
Average inventory
0
ROE
-0.7546
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
The EBITDA ratio is -11.08 highlighting the company's operational efficiency. Despite the challenges faced in its operations, the company reported a net loss of -$69,920,000.00 which indicates the difficulties it is encountering. However, Arbutus Biopharma Corporation achieved a revenue of $6,171,000.00 underscoring its focus on the niche market for novel therapeutics targeting chronic Hepatitis B virus (HBV) infection and coronaviruses such as SARS-CoV-2. The gross profit ratio is 0.78 reflecting the efficiency of the company's production and sales operations. Additionally, the reported depreciation and amortization expenses of $1,380,000.00 illustrate the wear and tear of its assets as they continue to develop their innovative product pipeline, including promising candidates like AB-729 and AB-836. The stock is affordable at $3.44 suitable for budget-conscious investors looking for entry points into the biopharmaceutical market. The stock has an average trading volume of 1,009,792.00 indicating moderate liquidity, which can appeal to investors seeking a balance between risk and stability. With a market capitalization of $643,530,720.00 the company is classified as a small-cap player, positioning it as a key player in the Biotechnology industry and contributing significantly to the overall market landscape. It belongs to the Healthcare sector, driving innovation and growth with a committed focus on addressing chronic viral infections through its strategic partnerships and clinical collaborations.
Is Arbutus Biopharma Corporation (ABUS) a good investment?
Investing in Arbutus Biopharma Corporation (ABUS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is Arbutus Biopharma Corporation (ABUS)'s stock forecast?
Analysts predict Arbutus Biopharma Corporation stock to fluctuate between $2.71 (low) and $4.72 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Arbutus Biopharma Corporation's market capitalization?
As of 2025-05-30, Arbutus Biopharma Corporation's market cap is $643,530,720, based on 191,527,000 outstanding shares.
How does Arbutus Biopharma Corporation compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Arbutus Biopharma Corporation has a Lower Market-Cap, indicating a difference in performance.
How can I buy Arbutus Biopharma Corporation (ABUS) stock?
To buy Arbutus Biopharma Corporation (ABUS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABUS. Place an order (Market, Limit, etc.).
What is the best time to invest in Arbutus Biopharma Corporation?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Arbutus Biopharma Corporation stock ever split?
Arbutus Biopharma Corporation's last stock split was 1:5 on 2010-11-04.
How did Arbutus Biopharma Corporation perform in the last earnings report?
Revenue: $6,171,000 | EPS: -$0.38 | Growth: -13.64%.
Where can I find Arbutus Biopharma Corporation's investor relations reports?
Visit https://www.arbutusbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Arbutus Biopharma Corporation?
You can explore historical data from here
What is the all-time high and low for Arbutus Biopharma Corporation stock?
All-time high: $6.50 (2021-12-01) | All-time low: $1.69 (2023-10-23).
What are the key trends affecting Arbutus Biopharma Corporation stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.10 per share a year ago.
globenewswire.com
Imdusiran combination therapy has functionally cured 8 patients with chronic hepatitis B (cHBV) to date, including 2 patients who received no interferon
globenewswire.com
Data highlighted in late-breaker poster presentation shows that imdusiran achieves functional cure in chronic hepatitis B (cHBV) patients when combined with VTP-300 and low dose nivolumab In a Phase 1a/1b clinical trial, AB-101, an oral PD-L1 inhibitor, has shown to be generally safe and well-tolerated with evidence of high receptor occupancy and no liver dysfunction in cHBV patients WARMINSTER, Pa., May 07, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced the presentation of five posters, including one late-breaker, highlighting imdusiran, its RNAi therapeutic and AB-101, its oral PD-L1 inhibitor, at the European Association for the Study of the Liver (EASL) Congress 2025.
globenewswire.com
Five abstracts accepted for poster presentations WARMINSTER, Pa., April 23, 2025 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that five abstracts, including one late-breaker, have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2025 taking place May 7 - 10, 2025 in Amsterdam, Netherlands.
zacks.com
Arbutus Biopharma (ABUS) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.12 per share a year ago.
globenewswire.com
Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending
See all news
